Other News To Note
Wednesday, September 5, 2012
Cellerant Therapeutics Inc., of San Carlos, Calif., was awarded $36.4 million by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy to treat acute radiation syndrome (ARS). The third year of funding is part of a five-year BARDA award valued at up to $169.9 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.